BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richardson SI, Moore PL. Targeting Fc effector function in vaccine design. Expert Opin Ther Targets 2021;25:467-77. [PMID: 33754933 DOI: 10.1080/14728222.2021.1907343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Keeton R, Richardson SI, Moyo-Gwete T, Hermanus T, Tincho MB, Benede N, Manamela NP, Baguma R, Makhado Z, Ngomti A, Motlou T, Mennen M, Chinhoyi L, Skelem S, Maboreke H, Doolabh D, Iranzadeh A, Otter AD, Brooks T, Noursadeghi M, Moon JC, Grifoni A, Weiskopf D, Sette A, Blackburn J, Hsiao NY, Williamson C, Riou C, Goga A, Garrett N, Bekker LG, Gray G, Ntusi NAB, Moore PL, Burgers WA. Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner. Cell Host Microbe 2021;29:1611-1619.e5. [PMID: 34688376 DOI: 10.1016/j.chom.2021.10.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nawab DH. Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects. Hum Vaccin Immunother 2021;:1-14. [PMID: 34844516 DOI: 10.1080/21645515.2021.1985891] [Reference Citation Analysis]
3 Richardson SI, Manamela NP, Motsoeneng BM, Kaldine H, Ayres F, Makhado Z, Mennen M, Skelem S, Williams N, Sullivan NJ, Misasi J, Gray GG, Bekker LG, Ueckermann V, Rossouw TM, Boswell MT, Ntusi NAB, Burgers WA, Moore PL. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep Med 2022;3:100510. [PMID: 35233544 DOI: 10.1016/j.xcrm.2022.100510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 12.0] [Reference Citation Analysis]
4 Wang C, Li Y, Kaplonek P, Gentili M, Fischinger S, Bowman KA, Sade-Feldman M, Kays KR, Regan J, Flynn JP, Goldberg MB, Hacohen N, Filbin MR, Lauffenburger DA, Alter G, Li JZ. The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia. mBio 2022;:e0157722. [PMID: 35762593 DOI: 10.1128/mbio.01577-22] [Reference Citation Analysis]
5 Richardson SI, Ayres F, Manamela NP, Oosthuysen B, Makhado Z, Lambson BE, Morris L, Moore PL. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function. Front Immunol 2021;12:733958. [PMID: 34566999 DOI: 10.3389/fimmu.2021.733958] [Reference Citation Analysis]
6 Lin LY, Carapito R, Su B, Moog C. Fc receptors and the diversity of antibody responses to HIV infection and vaccination. Genes Immun 2022. [PMID: 35688931 DOI: 10.1038/s41435-022-00175-7] [Reference Citation Analysis]
7 Walsh SR, Seaman MS. Broadly Neutralizing Antibodies for HIV-1 Prevention. Front Immunol 2021;12:712122. [PMID: 34354713 DOI: 10.3389/fimmu.2021.712122] [Reference Citation Analysis]
8 Cheong Y, Kim M, Ahn J, Oh H, Lim J, Chae W, Yang SW, Kim MS, Yu JE, Byun S, Jang YH, Seong BL. Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant. Front Immunol 2021;12:769088. [PMID: 34868027 DOI: 10.3389/fimmu.2021.769088] [Reference Citation Analysis]